Kurt Cann (dwlkurt24357)
Who Else Wants To Know The Mystery Behind a Hundred Nacked Girls?
Depoortere R, Dargazanli G, Estenne-Bouhtou G, Coste A, Lanneau C, Desvignes C, Poncelet M, Heaulme M, Santucci V, Decobert M, Cudennec A, Voltz C, Boulay D, Terranova JP, StemmelinJ, Roger P, Marabout B, Sevrin M, Vige X, Biton B, Steinberg R, Francon D, Alonso R, Avenet P, Oury-Donat F, Perrault G, Griebel G, George P, Soubrie P, Scatton B (2005) Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a prospective new form of antipsychotic. Psychopharmacology (Berl) 209, 263-270. Boulay D, Pichat P, Dargazanli G, Estenne-Bouhtou G, Terranova JP, Rogacki N, Stemmelin J, Coste A, Lanneau C, Desvignes C, Cohen C, Alonso R, Vige X, Biton B, Steinberg R, Sevrin M, Oury-Donat F, George P, Bergis O, Griebel G, Avenet P, Scatton B (2008) Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in types predictive of therapeutic exercise in schizophrenia. Pharmacol Biochem Behav 91, 47-58. Boulay D, Bergis O, Avenet P, Griebel G (2010) The glycine transporter-1 inhibitor SSR103800 shows a selective and specific antipsychotic-like profile in standard and transgenic mice. Neuropsychopharmacology 35, 416427. Black MD, Varty GB, Arad M, Barak S, De LA, Boulay D, Pichat P, Griebel G, Weiner I (2009) Procognitive and antipsychotic efficacy of glycine transport one inhibitors (GlyT1) in acute and neurodevelopmental designs of schizophrenia: Latent inhibition scientific tests in the rat.
Nihon Yakurigaku Zasshi 89, 145-153. Anami K, Setoguchi M, Senoh H (1988) Pharmacological experiments on Y-8894. Nihon Yakurigaku Zasshi 85, 71-77. Anami K, Yamamoto Y, Setoguchi M, Maruyama Y (1987) Pharmacological scientific tests on Y-8894. Lucelan, Metatone, teniloxazine, Y 8894. Drugs R D 2, 66-67. Anami K, Yamamoto Y, Setoguchi M (1985) Pharmacological reports on sufoxazine (Y-8894). Jpn J Pharmacol 79, 113-115. Shirayama Y, Yamamoto A, Nishimura T, Katayama S, Kawahara R (2007) Subsequent exposure to the choline uptake enhancer MKC-231 antagonizes phencyclidineinduced behavioral deficits and reduction in septal cholinergic neurons in rats. Jpn J Pharmacol 76, 219-222. Uemura K, Yoshioka S, Surina-Baumgartner DM, Tamagawa T, Miura H, Ueda M, Tamaya N, Iguchi A, Hotta N (1999) Central nervous procedure-mediated hyperglycemic outcomes of NIK-247, a cholinesterase inhibitor, and MKC231, a choline uptake enhancer, in rats. J Nucl Med 51, 14801485. Okamura N, Villemagne VL, Drago J, Pejoska S, Dhamija RK, Mulligan RS, Ellis JR, Ackermann U, O’Keefe G, Jones G, Kung HF, Pontecorvo MJ, Skovronsky D, Rowe CC (2010) In vivo measurement of vesicular monoamine transporter kind 2 density in Parkinson disease with (18)FAV-133. J Nucl Med 51, 223-228. Villemagne VL, Okamura N, Pejoska S, Drago J, Mulligan RS, Chetelat G, Ackermann U, O’Keefe G, Jones G, Gong S, Tochon-Danguy H, Kung HF, Masters CL, Skovronsky DM, Rowe CC (2011) In vivo evaluation of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer ailment.
J Nucl Med 46, 936-944. Gilman S, Koeppe RA, Little R, An H, Junck L, Giordani B, Livestreamingporn.com Persad C, Heumann M, Wernette K (2004) Striatal monoamine terminals in Lewy physique dementia and Alzheimer’s illness.
